This survey reveals the devastating effects of the COVD-19 pandemic on oncological surgery in Europe and may serve as an impulse for a critical re-evaluation and reasonable calibration of capacity allocation with regards to the high therapeutic value of surgical oncology, especially in GI and HPB tumour patients.